Kobayashi Pharmaceuticals Sustainability Profile
Kobayashi Pharmaceuticals Co., Ltd., commonly known as Kobayashi, is a leading player in the pharmaceutical and consumer healthcare industry, headquartered in Japan. Established in 1907, the company has a rich history marked by innovation and growth, with significant operations across Asia and beyond. Kobayashi is renowned for its diverse range of products, including over-the-counter medications, personal care items, and health supplements. Their unique formulations and commitment to quality set them apart in a competitive market. With a strong focus on research and development, Kobayashi has achieved notable milestones, solidifying its position as a trusted name in healthcare. The company continues to excel, leveraging its expertise to meet the evolving needs of consumers, while maintaining a reputation for excellence in product efficacy and safety.
DitchCarbon Score
How does Kobayashi Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kobayashi Pharmaceuticals's score of 45 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kobayashi Pharmaceuticals's reported carbon emissions
In 2024, Kobayashi Pharmaceuticals reported total carbon emissions of approximately 8,000,000 kg CO2e for Scope 1 and about 19,000,000 kg CO2e for Scope 2 (market-based), with an additional 386 kg CO2e attributed to Scope 3 emissions from purchased goods and services. This data reflects a commitment to transparency in their environmental impact. Kobayashi Pharmaceuticals has set ambitious reduction targets, committing to a 51% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2030, using 2018 as the base year. Additionally, the company aims to reduce its absolute Scope 3 emissions by 15% within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to contribute to global efforts to limit temperature rise to 1.5°C. In previous years, the company reported Scope 1 emissions of approximately 6,000,000 kg CO2e in 2022 and 8,000,000 kg CO2e in 2024, indicating a focus on reducing operational emissions. The total Scope 2 emissions for 2022 were reported at about 18,000,000 kg CO2e (market-based) and 21,000,000 kg CO2e (location-based). Kobayashi Pharmaceuticals' commitment to sustainability is evident through its structured approach to emissions reduction and adherence to industry standards, positioning itself as a responsible player in the consumer durables sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | - | - | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000 |
How Carbon Intensive is Kobayashi Pharmaceuticals's Industry?
How Carbon Intensive is Kobayashi Pharmaceuticals's Location?
Kobayashi Pharmaceuticals's Scope 3 Categories Breakdown
Kobayashi Pharmaceuticals's Scope 3 emissions, which decreased by 100% last year and decreased by approximately 100% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Purchased Goods and Services" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Kobayashi Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Kobayashi Pharmaceuticals has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Kobayashi Pharmaceuticals's sustainability data and climate commitments